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Michele Parker, MS, RN,‡ Mary J. Roman, MD,* Richard B. Devereux, MD*
New York, New York; and Durham, North Carolina
O B J E C T I V E S This study sought to compare contrast-enhanced anatomic imaging and contrast-
enhanced tissue characterization (delayed-enhancement cardiac magnetic resonance [DE-CMR]) for left
ventricular (LV) thrombus detection.
B A C KG ROUND Contrast echocardiography (echo) detects LV thrombus based on anatomic appear-
ance, whereas DE-CMR imaging detects thrombus based on tissue characteristics. Although DE-CMR has
been validated as an accurate technique for thrombus, its utility compared with contrast echo is unknown.
METHOD S Multimodality imaging was performed in 121 patients at high risk for thrombus due to
myocardial infarction or heart failure. Imaging included 3 anatomic imaging techniques for thrombus
detection (contrast echo, noncontrast echo, cine-CMR) and a reference of DE-CMR tissue characteriza-
tion. LV structural parameters were quantiﬁed to identify markers for thrombus and predictors of
additive utility of contrast-enhanced thrombus imaging.
R E S U L T S Twenty-four patients had thrombus by DE-CMR. Patients with thrombus had larger
infarcts (by DE-CMR), more aneurysms, and lower LV ejection fraction (by CMR and echo) than those
without thrombus. Contrast echo nearly doubled sensitivity (61% vs. 33%, p  0.05) and yielded
improved accuracy (92% vs. 82%, p  0.01) versus noncontrast echo. Patients who derived incremental
diagnostic utility from DE-CMR had lower LV ejection fraction versus those in whom noncontrast echo
alone accurately assessed thrombus (35  9% vs. 42  14%, p  0.01), with a similar trend for patients
who derived incremental beneﬁt from contrast echo (p  0.08). Contrast echo and cine-CMR closely
agreed on the diagnosis of thrombus (  0.79, p  0.001). Thrombus prevalence was lower by contrast
echo than DE-CMR (p  0.05). Thrombus detected by DE-CMR but not by contrast echo was more likely
to be mural in shape or, when apical, small in volume (p  0.05).
CONC L U S I O N S Echo contrast in high-risk patients markedly improves detection of LV thrombus, but
does not detect a substantial number of thrombi identiﬁed by DE-CMR tissue characterization. Thrombi
detected by DE-CMR but not by contrast echo are typically mural in shape or small in volume. (J Am Coll
Cardiol Img 2009;2:969–79) © 2009 by the American College of Cardiology Foundation
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970ccurate detection of left ventricular (LV)
thrombus is important as thrombus pro-
vides a substrate for embolic events and a
rationale for anticoagulation. Both echo-
ardiography (echo) and cardiac magnetic reso-
ance (CMR) imaging can use contrast agents to
mprove thrombus detection. Echo contrast typi-
ally improves thrombus detection through cavity
pacification, identifying thrombus based on ana-
omic appearance. CMR uses contrast to identify
hrombus based on tissue characteristics related
o avascularity. Using the technique of delayed-
nhancement (DE)-CMR, which is widely used to
iscern viable from infarcted myocardium, throm-
us can be identified by absence of contrast uptake.
ecause DE-CMR identifies thrombus based on
issue characteristics rather than anatomic appear-
nce, it enables LV thrombus to be delineated from
yocardium and chamber cavity irrespective of
ocation or morphology.
DE-CMR has been well validated as an
accurate technique for LV thrombus based
on comparisons with pathology findings
and clinical embolic events (1,2). In prior
studies, DE-CMR has yielded a 2- to
3-fold improvement in thrombus detec-
tion versus noncontrast echo (2,3). How-
ever, comparative studies have been per-
formed without routine use of echo
contrast, which can improve thrombus
detection (4). Additionally, indications for
contrast use differ between CMR and
echo. For CMR, almost all studies include
DE-CMR for the primary purpose of
istinguishing between viable and infarcted myo-
ardium, meaning that virtually all patients receive
ontrast. For echo, consensus guidelines recom-
end that contrast be reserved for noncontrast
tudies with suboptimal image quality (5). The
tility of a strategy of echo contrast administration
ased on a priori clinical risk for thrombus rather
han noncontrast echo image quality is unknown.
ecause echo is widely used to screen patients with
oronary disease or heart failure at risk for LV
hrombus, optimization of diagnostic strategies for
hrombus detection is of substantial importance.
The aims of this study were: 1) to compare
ultiple imaging techniques that identify thrombus
ased on anatomic appearance (noncontrast echo,
ontrast echo, and cine-CMR) to a reference of
E-CMR tissue characterization; 2) to assess
hether thrombus detection by anatomic imaging
ionaries in relation to LV geometry or thrombus qorphology; and 3) to identify imaging markers for
V thrombus in an at-risk population.
E T H O D S
atients. The population consisted of patients at
igh risk for LV thrombus because of recent myo-
ardial infarction or chronic heart failure who un-
erwent a multimodality imaging protocol at Weill
ornell Medical College between August 2005 and
ovember 2007. Patients were enrolled if CMR
nd echo were performed within a 7-day interval.
ll patients had contrast echo performed for the
rimary indication of LV thrombus assessment;
5% were clinically referred for CMR and 45%
ere recruited via an ongoing study of post-
yocardial infarction thrombus and remodeling.
or all patients, imaging was performed in accor-
ance with a pre-defined protocol and interpreted
y pre-assigned readers blinded to clinical history
nd results of other imaging modalities. Patients
ere enrolled de novo and none had participated in
rior investigations concerning thrombus (1).
The imaging protocol consisted of noncontrast
cho, contrast echo, cine-CMR, and DE-CMR.
ontrast echo was performed irrespective of quality
r findings of noncontrast echo; 60.3% of patients
ad echo and CMR performed on the same day,
2.2% underwent CMR at least one day before
cho, and 7.4% underwent echo before CMR.
linical data were collected, including cardiac risk
actors, presence of coronary artery disease, and
edication regimen. Pathology data (in patients
ndergoing LV reconstruction surgery within 1
onth) were reviewed to verify thrombus as iden-
ified at the time of imaging.
All procedures were conducted in accordance with
he institutional review board at Weill Cornell, which
pproved the study protocol. All prospectively re-
ruited patients provided informed consent and the
nstitutional review board approved use of pre-existing
ata for inclusion in the imaging registry.
maging protocol. The full protocol is available
nline.
MR. CMR was performed using 1.5-T scanners
General Electric, Waukesha, Wisconsin). Cine-
MR was performed using a steady-state free preces-
ion sequence. Gadolinium was then intravenously
dministered (0.2 mmol/kg) to patients without con-
raindications (glomerular filtration rate30 ml/min/
.73 m2) (6). DE-CMR was performed 10 min
hereafter using a segmented inversion recovery se-B B R E V I A T I O N S
N D A C R O N YM S
MR cardiac magnetic
esonance
E delayed-enhancement
cho echocardiography
V left ventricular
VEF left ventricular eject
raction
VOmicrovascular
bstructionuence (7). Cine-CMR and DE-CMR images were
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971cquired in matching planes. Short-axis imaging was
ontiguous throughout the LV. Long-axis images
ere acquired in 2-, 3- and 4-chamber orientations.
CHO. Echocardiograms were performed using
ommercial equipment (General Electric Vivid-7 or
iemens [Malvern, Pennsylvania] Sequoia) by
onographers who had undergone dedicated train-
ng concerning the imaging protocol. Noncontrast
mages were acquired in standard parasternal and
pical imaging planes (5). A sonographic contrast
gent (Definity, Lantheus Medical Imaging, North
illerica, Massachusetts) was then administered in
ccordance with manufacturer guidelines (8).
oncontrast- and contrast-enhanced images were
cquired in at least 3 (2-, 3-, and 4-chamber) apical
rientations.
hrombus identiﬁcation. TISSUE CHARACTERIZATION.
hrombus was identified on DE-CMR as a mass
ith tissue characteristics consistent with avascular
issue (1,2). DE-CMR was performed in accordance
ith the thrombus protocol that has been validated in
rior research by our group (1). Standard DE-CMR
as performed using an inversion time (TI) tailored to
ull viable myocardium (297  31 ms, range 200 to
50 ms). On standard DE-CMR, thrombus typically
ad a gray etched appearance compared with black
viable) or white (infarcted) myocardium (Fig. 1A,
tandard TI). To further delineate thrombus, addi-
ional DE-CMR imaging was performed using a
ulse sequence tailored to null avascular tissue (1). By
ncreasing the TI to 600 ms, regions with contrast
ptake appear gray and thrombus appears black (Fig.
A, long TI). Scanner operators performed standard
E-CMR in all patients and long TI imaging in
atients (72%) that tolerated additional breath-holds.
In accordance with established criteria (1,3),
hrombus was distinguished from myocardial in-
arction with microvascular obstruction (MVO)
ased on: 1) surrounding structures (MVO encom-
assed by hyperenhanced myocardium); 2) appear-
nce (MVO within myocardium, thrombus adja-
ent to LV cavity and typically involves abrupt
ndocardial transitions); and 3) stability of size on
onsecutive DE-CMR images (MVO shrinks from
eripheral contrast fill-in, thrombus size stable).
NATOMIC IMAGING. For cine-CMR and echo,
hrombus was diagnosed based on anatomic appear-
nce and defined as an LV mass that was distin-
uishable from papillary muscles, trabeculae,
hordal structures, technical artifact, or tangential
iews of the LV wall (1,9). Thrombus was schodense on echo, and signal intensity was similar
o myocardium on cine-CMR.
ata analysis. THROMBUS ASSESSMENT. Each mo-
ality was interpreted during a separate reading
ession by an experienced physician (CMR or echo
merican Heart Association/American College of
ardiology Level III) who was blinded to the
esults of other modalities and clinical history.
nterobserver reproducibility was assessed by having
second reader independently reinterpret each
odality for 30 randomly selected patients. All
choes were reviewed for image quality, which was
raded using a scale combining scores for endocar-
ial border definition (1  poor, 2  fair, 3 
xcellent) and cavity artifacts (1  present/
bscuring full assessment, 2  present/not prevent-
ng interpretation, 3  absent).
Thrombus volume, morphology, and location
ere scored on DE-CMR; volume was quantified
y planimetry. Morphology was classified as mural
borders concave, similar to surrounding endocar-
ial contours) or intracavitary (borders protruding
nto the cavity, distinct from surrounding endocar-
ial contours) (1,10). Location was classified as
pical if localized to the LV apex or apical segments
f other LV walls.
MAGING MARKERS. CMR and echo indexes were
easured to determine relationships with thrombus.
oncontrast echo quantified left ventricular ejection
raction (LVEF) and chamber size based on linear
imensions (5). Cine-CMR quantified LVEF and
hamber volumes based on planimetry. Regional con-
ractility and infarction were scored using a 17-
egment model. Segmental function was graded on
ine-CMR (0 normal contraction, 1 mild hypo-
inesia, 2  moderate hypokinesia, 3  severe hypo-
inesia, 4  akinesia, 5  dyskinesia). Cine-CMR
nd echo were scored for presence of LV aneurysms.
E-CMR was scored for infarct size based on trans-
ural extent of hyperenhancement (0  none, 1 
% to 25%, 2  26% to 50%, 3  51% to 75%, 4 
6% to 100%). Global infarct size was calculated by
umming segmental scores weighted by the midpoint
f the range of hyperenhancement and dividing by the
otal number of segments (11).
tatistical methods. Continuous variables were com-
ared using a student’s t test with the Levene test
or equality of variance to confirm homogeneity.
ariables were also tested for skew and kurtosis;
omparisons between non-normally distributed
ata (thrombus volumes) were based on logarithmic
ransformation. Limits of agreement (1.96  the
tandard deviation of between-method differences)
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972ere calculated. Categorical variables were com-
ared using chi-square or Fisher exact test. Diag-
ostic test performance and thrombus prevalence
ere compared using the McNemar test with exact
inomial probability calculations. Magnitude of
greement between tests was measured using the
appa statistic (). Univariate and multivariable
ogistic regression analyses were performed to eval-
ate associations between imaging parameters and
hrombus. Two-sided p  0.05 was considered
ndicative of statistical significance. Analyses were
erformed using SPSS version 12.0 (SPSS Inc.,
Figure 1. Apical Thrombus by Anatomic and Tissue Characteriza
(A) Representative example of apical thrombus (circle) concorda
4-chamber, cine-CMR 2-chamber) and DE-CMR (center). (B) Repre
DE-CMR. DE-CMR identiﬁed a small mural thrombus (circle) with
preted as negative. For both examples, surgical resection enable
lin and eosin stain, low power), which showed thrombus with as
delayed-enhancement.hicago, Illinois). iE S U L T S
opulation. The population consisted of 121 pa-
ients who underwent CMR and echo within a
ean interval of 0.8  1.4 days. Both modalities
howed advanced LV dysfunction (LVEF differ-
nce 0.5  6.9% p  0.42, limits of agreement
13.2% to 14.2%).
E-CMR thrombus. DE-CMR identified LV
hrombus in 24 of 121 patients (20%). Pathology
erification of thrombus was available in 3 patients,
ll of whom had thrombus by DE-CMR. As shown
Imaging
detected by anatomic imaging (left, contrast echocardiography
tative example of discordance between anatomic imaging and
e apex. Cine-CMR and contrast echocardiography were inter-
rombus veriﬁcation based on histopathology (right, hematoxy-
ated ﬁbroblasts (*). CMR  cardiac magnetic resonance; DE tion
ntly
sen
in th
d th
socin Table 1, patients with thrombus did not differ
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973Table 1. Population Characteristics
Overall
(n  121)
DE-CMR  Thrombus
(n  24)
DE-CMR  Thrombus
(n  97) p Value
Clinical
Age (yrs) 61.2  13.3 58.0  14.6 61.9  12.9 0.19
Male sex 77% (93) 83% (20) 75% (73) 0.40
New York Heart Association functional class 2.0  0.8 2.5  0.8 1.8  0.8 0.007
Coronary artery disease risk factors
Hypertension 67% (81) 67% (16) 67% (65) 0.97
Hypercholesterolemia 88% (107) 92% (22) 88% (85) 0.73
Diabetes mellitus 33% (40) 42% (10) 31% (30) 0.32
Tobacco use 33% (40) 38% (9) 32% (31) 0.61
Family history 21% (25) 29% (7) 19% (18) 0.27
Coronary artery disease 98% (118) 100% (24) 97% (94) 1.0
Prior myocardial infarction
Any history before CMR 83% (100) 79% (19) 84% (81) 0.56
Within 2 months before CMR* 69% (84) 71% (17) 69% (67) 0.87
Coronary revascularization
Percutaneous intervention 59% (71) 42% (10) 63% (61) 0.06†
Coronary artery bypass grafting 10% (12) 8% (2) 10% (10) 1.0
Atrial ﬁbrillation 6% (7) — 7% (7) 0.34
Lifetime history of cerebrovascular event
Cerebrovascular accident 11% (13) 13% (3) 10% (10) 0.72
Transient ischemic attack 3% (4) — 4% (4) 0.58
Cerebrovascular accident or transient ischemic attack 12% (15) 13% (3) 12% (12) 1.0
Cardiovascular medications
Beta-blocker 78% (94) 79% (19) 77% (75) 0.85
ACE inhibitor or angiotensin receptor blocker 67% (81) 79% (19) 64% (62) 0.16
Loop diuretic 17% (20) 21% (5) 16% (15) 0.55
HMG-CoA reductase inhibitor 79% (96) 88% (21) 77% (75) 0.40
Antithrombotic medications
Aspirin 85% (103) 96% (23) 83% (80) 0.12
Warfarin 9% (11) 4% (1) 10% (10) 0.69
Thienopyridines 44% (53) 33% (8) 46% (45) 0.25
Echocardiography
LV function and morphology
Ejection fraction (%) 40.4  13.1 33.6  8.9 42.0  13.5 0.001
End-diastolic diameter (cm) 5.9  0.7 6.1  1.0 5.9  0.6 0.39
End-systolic diameter (cm) 4.8  0.9 5.1  1.1 4.7  0.8 0.03
Aneurysm present 13% (16) 25% (6) 10% (10) 0.09†
Cardiac magnetic resonance
LV function and morphology
Ejection fraction (%) 39.9  13.9 30.3  11.0 42.0  13.6 <0.001
Wall motion score index 1.6  0.9 2.2  0.8 1.5  0.9 0.001
End-diastolic volume (ml) 182.9  72.7 212.5  113.4 176.3  58.7 0.16
End-systolic volume (ml) 116.4  72.7 157.0  113.3 107.2  56.7 0.06†
Myocardial mass (g) 166.1  55.7 192.4  65.9 160.2  51.6 0.01
Aneurysm present 12% (15) 29% (7) 8% (8) 0.01
LV infarction
% LV with transmural infarction‡ 17.2  13.3 24.8  12.5 15.3  12.8 0.001
% LV infarct size 17.6  10.5 24.6  8.6 15.9  10.2 <0.001
Anterior wall infarction 69% (83) 92% (22) 63% (61) 0.007
Inferior or lateral wall infarction 63% (76) 71% (17) 61% (59) 0.36
Boldface type indicates p  0.05. *Mean 3.1  1.7 weeks before CMR. †Indicates p  0.1. ‡Calculated based on aggregate number of segments with transmural extent of infarction 50%.
ACE  angiotensin-converting enzyme; CMR  cardiac magnetic resonance; DE  delayed-enhancement; HMG-CoA  3-hydroxy-3-methyl-glutaryl-coenzyme A; LV  left ventricular.
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974ignificantly from those without thrombus in age,
ex, or coronary artery disease risk factors. However,
atients with thrombus had more severe LV dys-
unction as measured by New York Heart Associ-
tion functional class (p  0.007) and the imaging
arameters of LVEF (p  0.001) or aneurysmal
ilation by echo (p  0.09) or cine-CMR (p 
.01). Patients with thrombus also had larger total
nd transmural infarct size as measured by DE-
MR (p  0.001).
Multivariable analyses were performed to identify
maging parameters associated with LV thrombus.
eparate models were used to examine whether
ransmural myocardial infarction by DE-CMR was
n independent marker for thrombus after adjust-
ent for measures of chamber function and mor-
hology derived from either cine-CMR or echo.
hen considering only CMR parameters (Table
), transmural infarct size was an independent
arker for thrombus after adjustment for LVEF
nd aneurysmal dilation. A similar relationship was
een when substituting echo-derived LVEF in the
ultivariate model, although echo-identified LV
neurysm was not an independent marker for
hrombus (Table 2). Both models showed that the
elationship between thrombus and infarction was
Table 2. Imaging Markers for LV Thrombus*
Variable
Cardiac magnetic resonance (function  remodeling  infarction)
Chi-square  23.1, p  0.001
LV ejection fraction† (cine-CMR)
LV aneurysm (cine-CMR)
LV with transmural infarction‡ (DE-CMR)
Echo (function  remodeling)  DE-CMR (infarction)
Chi-square  17.0, p  0.001
LV ejection fraction† (echo)
LV aneurysm (echo)
LV with transmural infarction‡ (DE-CMR)
*Indexes calculated using DE-CMR as the standard for LV thrombus. †Per 10-p
infarction.
Abbreviations as in Table 1.
Table 3. Diagnostic Performance of Anatomic Imaging for LV Th
Sensitivity Speciﬁcity
Noncontrast echocardiography 33% (8/24) 94% (91/97)
Contrast echocardiography 61% (14/23)‡ 99% (96/97)
Cine-CMR 79% (19/24)† 99% (96/97)
*Indexes calculated using DE-CMR as the standard for LV thrombus. †p  0.001
echo). One patient (with thrombus by noncontrast echo, cine-CMR, and DE-CM
because of contraindications to the echo contrast agent (8) in the interim betw
Abbreviations as in Table 1.ontinuous, such that likelihood of thrombus in-
reased in proportion to infarct size with an approx-
mate 40% increase in relative risk for every 10%
ncrement in transmural infarction.
iagnostic performance of anatomic imaging. Table 3
eports diagnostic performance of anatomic imag-
ng techniques compared with a reference of DE-
MR. Echo contrast markedly improved diagnos-
ic performance for thrombus detection in this
igh-risk population. Sensitivity improved nearly
-fold versus noncontrast echo (p 0.05), resulting
n substantially higher accuracy (p  0.01). Similar
o contrast echo, cine-CMR provided markedly
igher sensitivity and accuracy versus noncontrast
cho (p  0.001). There were no significant differ-
nces in diagnostic indexes between contrast echo
nd cine-CMR, with strong agreement between
odalities for the diagnosis of thrombus (  0.79,
 0.001). Diagnostic performance of echo was
imilar between patients grouped according to dif-
erences in testing sequence between CMR and
cho as evidenced by nonsignificant differences in
ccuracy of contrast echo (p  0.37) and noncon-
rast echo (p  0.11) between groups.
Among the patent subgroup that underwent
einterpretation of images, interobserver agreement
Odds Ratio 95% Conﬁdence Interval p Value
1.63 1.17–2.11 0.007
4.43 1.25–15.69 0.02
1.39 1.01–1.79 0.04
1.58 1.11–2.07 0.01
2.53 0.56–7.50 0.28
1.43 1.04–1.83 0.03
decrement in LV ejection fraction. ‡Per 10% LV myocardium with transmural
bus*
Accuracy
Positive Predictive
Value
Negative Predictive
Value
82% (99/121) 57% (8/14) 85% (91/107)
92% (110/120)§ 93% (14/15) 91% (96/105)
95% (115/121)† 95% (19/20) 95% (96/101)
oncontrast echo). ‡p  0.05 (vs. noncontrast echo). §p  0.01 (vs. noncontrast
ould not undergo the contrast echocardiography component of the protocol
study consent and imaging (decompensated heart failure).ointrom
(vs. n
R) c
een
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975reported as proportion of concordant reads and 
alue) was good for noncontrast echo (25 of 30; 
.52, p 0.003) and excellent for contrast echo (29
f 30;   0.87), cine-CMR (29 of 30;   0.91),
nd DE-CMR (30 of 30;  1.00) (all p 0.001).
redictors of improved contrast-echo thrombus detec-
ion. QUALITATIVE AND STRUCTURAL PARAMETERS.
ultiple parameters were examined for markers
hat could identify patients who derived incremen-
al diagnostic benefit from echo contrast. Table 4
eports image quality parameters for contrast and
oncontrast echo in the overall population and in
atients with thrombus detected or missed by each
cho technique. In the total population, echo con-
rast improved endocardial border definition, cavity
elineation, and overall image quality versus non-
ontrast echo (p  0.001). However, echo perfor-
ance was not associated with reader-assigned
uality, with similar values for all qualitative param-
ters between contrast and noncontrast echoes that
issed thrombus versus those that detected DE-
MR evidenced thrombus (p  NS). Similar rela-
ionships were shown when comparing image quality
cores between noncontrast echoes that independently
etected thrombus and those in which contrast use
rovided incremental utility for thrombus detection
p  NS).
Regarding LV quantitative parameters, noncon-
rast echoes that correctly identified or excluded
hrombus had less depressed systolic function com-
ared with echoes that were discordant with DE-
MR. As shown in Table 5, both cine-CMR and
cho showed that LVEF was lower (p  0.05)
mong patients with noncontrast echoes that were
iscordant with the DE-CMR diagnosis of throm-
us. Similarly, echo-evidenced LVEF tended to be
ower in patients in whom contrast echo improved
hrombus assessment versus those in whom non-
ontrast echo alone accurately assessed thrombus
34.2  9.9% vs. 41.2  13.3%, p  0.08). There
Table 4. Echo Image Quality in Relation to LV Thrombus Detect
Image Quality†
Overall
Population‡
Patients
With
Thrombus
Detected
Patients
With
Thrombus
Missed
p
Value
Noncontrast echo 4.66 1.45 4.13 1.73 4.06 1.39 0.92
Contrast echo 5.44 0.89 5.21 0.89 4.56 1.24 0.15
*Indexes calculated using DE-CMR as the standard for LV thrombus. ‡p  0.001
and cavity delineation scores.
Abbreviations as in Table 1.ere no significant differences in clinical parametersetween patients with thrombus detected and those
ith thrombus missed by noncontrast echo.
HROMBUS MORPHOLOGY. Despite the marked
verall improvement in thrombus detection yielded
y a routine strategy of contrast use, 39% of
E-CMR evidenced thrombi were not detected by
ontrast echo, resulting in lower overall prevalence
13%) compared with DE-CMR (20%; p  0.02).
hereas DE-CMR detected 14 of the 15 thrombi
etected by contrast echo (sensitivity 93% based on
cho reference), contrast echo identified 14 of 23
hrombi (61%) detected by DE-CMR. Impaired
hrombus detection was not specific to contrast
cho but was also evident for anatomic imaging by
MR, as shown by the fact that 21% of thrombi
ere missed by cine-CMR. Figures 1B and 2
rovide examples of patients with thrombus de-
ected by DE-CMR but missed by either contrast
cho or cine-CMR.
Detection of thrombus by anatomic imaging
aried according to location, type, and size. Overall,
5% of thrombi were apical in location and 67%
ere intracavitary in shape. Apical and nonapical
hrombi were similar in size (3.2  4.0 cm3 vs.
.4  7.4 cm3, p  0.7). Although apical thrombi
Table 5. LV Geometry and Function in Relation to Echo Perform
NC-Echo Concordance
With DE-CMR
NC-Echo D
With D
Echo
Ejection fraction (%) 41.6 13.5 34.5
End-systolic diameter (cm) 4.7 0.9 5.0
End-diastolic diameter (cm) 5.9 0.6 6.0
Aneurysmal dilation 12.1% 18.
Cine-CMR
Ejection fraction (%) 41.5 13.8 32.5
End-systolic volume (ml) 111.1 69.7 141.6
End-diastolic volume (ml) 179.4 70.2 199.5
Aneurysmal dilation 9.1% 27.
Boldface type indicates p  0.05. *p  0.1.
Endocardial Border Deﬁnition LV Cavity De
verall
ulation‡
Patients
With
Thrombus
Detected
Patients
With
Thrombus
Missed
p
Value
Overall
Population‡
Patients
With
Thrombus
Detected
 0.77 2.00 0.93 2.06 0.68 0.85 2.34 0.76 2.13 0.83
 0.59 2.50 0.52 2.22 0.67 0.28 2.83 0.42 2.71 0.47
all comparisons between contrast and noncontrast echo. †Aggregate scale compance
iscordance
E-CMR p Value
9.2 0.005
0.9 0.11
0.8 .46
2% .49
12.1 0.007
82.4 0.08*
83.5 0.25
3% 0.03ion*
lineation
O
Pop
Patients
With
Thrombus
Missed
p
Value
2.31 2.00 0.82 0.73
2.61 2.33 0.71 0.13
for rised of border deﬁnitionNC  noncontrast; other abbreviations as in Table 1.
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976issed by contrast echo were, on average, 20% as
arge as those detected (0.8  0.6 cm3 vs. 4.3  4.5
m3, p  0.02), nonapical thrombi missed by
ontrast echo varied widely in size with thrombi
issed (7.3  8.7 cm3, range 0.2 to 19.2 cm3)
ccasionally larger than those detected (1.5  1.1
0
2.5
5
7.5
10
Contrast Echo Non-Contrast Echo
p < 0.05 p < 0.1
Thrombus Detected Thrombus Missed
Thrombus Size in Relation to Echo Detection
mbi detected by contrast echocardiography were larger than
ed, with a similar trend for noncontrast echocardiography (data
Figure 2. Nonapical Thrombus Despite Negative Anatomic Imag
Representative example of nonapical thrombus detection by DE-CM
echocardiography (left, 2-chamber view) were negative for thrombu
of both short- and long-axis images. DE-CMR (right, 2-chamber view
inferior wall. Abbreviations as in Figure 1.s
mean  SD).m3, 0.8 to 2.3 cm3) (p  0.7). As shown in Figure
, a similar trend was observed for apical thrombi
issed versus detected by noncontrast echo (2.0 
.7 cm3 vs. 4.6  5.1 cm3, p  0.097). Thrombus
hape also modified detection by anatomic imaging,
ith mural thrombus less likely to be detected
y contrast echo and cine-CMR (both p  0.05).
alf (3 of 6) of all nonapical thrombi were mural
n shape.
I S C U S S I O N
his study, the first to simultaneously compare
ontrast and noncontrast echo with DE-CMR for
V thrombus, provides several new observations:
irst, among a high-risk population, thrombus
etection was markedly improved by a uniform
trategy of contrast-enhanced imaging. Patients
ho derived incremental benefit from DE-CMR or
ontrast echo had lower LVEF than those in whom
oncontrast echo alone accurately assessed throm-
us. Second, despite the marked improvement in
iagnostic performance yielded by echo contrast,
E-CMR detected more thrombi than did contrast
cho. Contrast echo limitations were not modality-
espite negative anatomic imaging. Noncontrast and contrast
ine-CMR (middle) identiﬁed thrombus, attributable to acquisition
entiﬁed a large mural thrombus (circle) adjacent to the basalTh
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Figure 3.
Apical thro
those missing
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) idpecific, as evidenced by the fact that cine-CMR
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977issed 21% of DE-CMR evidenced thrombi, with
ine-CMR and contrast echo less likely to detect
ural thrombus. Third, infarct size by DE-CMR
as an independent marker for thrombus even after
ontrolling for LVEF and aneurysmal dilation.
A major aim of our investigation was to compare
n established technique of thrombus tissue char-
cterization by DE-CMR (1,2) with multiple tech-
iques that identify thrombus based on anatomic
ppearance. Two-thirds of DE-CMR–evidenced
hrombi were not detected by noncontrast echo,
hereas contrast-echo improved sensitivity nearly
-fold. Although it is possible that interval resolu-
ion of thrombus may have contributed to differ-
nces in test performance between echo and CMR,
he interval between modalities was short (0.8 1.4
ays) and the additive value of contrast-enhanced
maging was shown for echo and CMR, supporting
he concept that improved thrombus detection was
elated to contrast enhancement.
When interpreting these results, it is important
o recognize that there was no uniform gold stan-
ard for thrombus and that there are inherent
imitations to using any given imaging method as a
eference standard. However, our study was predi-
ated on prior research that used pathology and
linical data to validate DE-CMR as a highly
ccurate technique for thrombus (1,2). Consistent
ith our findings, prior studies have reported that
E-CMR improves thrombus detection versus
cho. In a study that included 12 patients with
E-CMR–evidenced thrombus, Mollet et al. (3)
eported that echo detected thrombus in 42%.
richai et al. (2), studying patients with uniform
athology verification of thrombus, reported that
ensitivity of echo was 23% versus 88% for CMR.
owever, both studies may have understated echo
apabilities. In the former, comparisons were exclu-
ively made with noncontrast echo. In the latter,
MR with uniform gadolinium use was retrospec-
ively compared with echo with only occasional use
f echo contrast.
A central aspect of our protocol involved uniform
cho contrast use irrespective of diagnostic findings
r image quality of noncontrast echo. Our results
how that routine administration of echo contrast
nd dedicated imaging protocols can improve
hrombus detection in at-risk patients. Our findings
re especially pertinent in the context of recent
roduct labeling changes concerning risks of ultra-
ound contrast agents (8) and ensuing debate re-
arding the risks of echo contrast and the future of
idespread use in the context of these labeling ehanges (12,13). Although prior studies have re-
orted that echo contrast improves LV thrombus
etection, use has almost always been reserved for
elected patients with suboptimal noncontrast echo
uality (4,14). Our results show that although echo
ontrast improved image quality in the overall
opulation, image quality alone did not predict
mproved thrombus assessment. For example,
mong patients with thrombus by DE-CMR, im-
ge quality scores did not differ between noncon-
rast echoes that detected thrombus and those in
hich contrast use provided additive benefit. This
an be partially explained by our observation that
hrombus can be present in areas other than the LV
pex and thereby missed despite high-quality apical
maging. The marked improvement in thrombus
ssessment yielded by echo contrast calls into ques-
ion consensus guidelines that primarily recom-
end contrast use based on noncontrast echo image
uality (5).
Our findings show that LV function can be
seful for guiding imaging strategies for thrombus.
oncontrast echoes that were discordant with DE-
MR had lower LVEF than those that were
oncordant with DE-CMR. Similarly, patients
ho derived incremental diagnostic utility from
cho contrast tended to have lower LVEF than
hose in whom noncontrast echo alone accurately
iagnosed thrombus. LVEF was predictive as mea-
ured by either echo or cine-CMR despite variance
etween the 2 modalities, with differences possibly
ttributable to the fact that cine-CMR used
lanimetry whereas echo used linear measurements.
rrespective of differences between modalities, our
ndings confirm a well-established association be-
ween contractile dysfunction and thrombus (1,9),
ith the incremental utility of contrast-enhanced
maging paralleling higher thrombus prevalence
ith impaired LVEF. Although DE-CMR pro-
ided improved thrombus detection versus both
ontrast and noncontrast echo, optimization of
cho protocols for thrombus remains important for
ituations in which echo is used to assess ventricular
unction, or in which DE-CMR is not available or
s contraindicated. As our results show improved
hrombus detection by DE-CMR, it is reasonable
o expect that the advantage of tissue characteriza-
ion is not modality specific. Perfusion echo can
dentify thrombus based on tissue characteristics
15), and our findings suggest that this approach
ay provide added benefit compared with contrastcho solely for LV cavity opacification.
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978It is important to recognize that this population
as at high pre-test risk for thrombus, as reflected
y the fact that 20% had thrombus by DE-CMR.
mong this high-risk population, transmural in-
arct size was a marker for thrombus even after
ontrolling for LVEF or aneurysmal dilation. This
nding is consistent with our prior study showing
hat infarct size by DE-CMR was associated with
hrombus among a diverse heart failure cohort (1).
owever, in our prior study, echo predictors were
ot evaluated. In this study, thrombus was associ-
ted with transmural infarct size even after control-
ing for LVEF and aneurysm measured by either
cho or cine-CMR, showing that infarcted myocar-
ium is an independent marker for thrombus irre-
pective of the modality used to assess LV function/
eometry.
tudy limitations. Several limitations should be rec-
gnized. First, breath-held DE-CMR can be diffi-
ult for some patients, and this can affect tolerance
f DE-CMR. Free-breathing alternatives, includ-
ng navigator or single-shot DE-CMR, were not
ested. Our protocol was limited to segmented
E-CMR to evaluate one validated method for
hrombus tissue characterization and provide a uni-
orm comparison with echo. Second, although our
tudy compared diagnostic performance of ana-
omic and tissue characterization imaging, the clin-
cal implications of thrombus detected by DE-with the use of intravenous second- 215–23.O N C L U S I O N S
hese findings show that DE-CMR is useful for
V thrombus detection among at-risk patients.
hrombus was associated with infarct size, an
dditional parameter provided by DE-CMR. Al-
hough echo diagnostic performance was markedly
mproved by a strategy of routine contrast use,
revalence was lower than by DE-CMR, especially
or mural thrombus and small apical thrombus.
ine-CMR and contrast echo showed similar per-
ormance and strong agreement, suggesting that
imitations were not modality specific but rather
ere attributable to intrinsic features of imaging
echniques that identify LV thrombus based on
natomic appearance without assessment of tissue
roperties.
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